Contract drug manufacturers are investing billions of dollars in expanding or constructing facilities that fill the injection pens used for weight-loss drugs like Novo Nordisk A/S's (NYSE: NVO) Wegovy.
Interviews with industry insiders reveal fierce competition among pharmaceutical services companies to secure contracts for filling the syringes used in these pens, known as fill-finish.
This race is driven by Wegovy and the anticipation of Eli Lilly And Co's (NYSE: LLY) Mounjaro entering the weight-loss market in the U.S. this year.
Obesity treatment, Wegovy, has experienced a surge ...